Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including FDA approvals and a ...

The company has an inhibitor of CSF1R – vimseltinib – which is due to start a phase 1/2 trial in tenoysynovial giant cell tumour (TGCT) before the end of the year. Other early-stage programmes ...

Department of Orthopedics, General Hospital of Northern Theater Command, Shenyang, China Background: Osteoarthritis (OA) is a degenerative disease with a high incidence worldwide. Most affected ...